Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Accounts Payables: 2019-2025

Historic Accounts Payables for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to $2.3 million.

  • Keros Therapeutics' Accounts Payables fell 53.86% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 53.86%. This contributed to the annual value of $4.6 million for FY2024, which is 15.56% down from last year.
  • Keros Therapeutics' Accounts Payables amounted to $2.3 million in Q3 2025, which was down 56.37% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Accounts Payables ranged from a high of $7.7 million in Q2 2022 and a low of $1.4 million during Q2 2021.
  • Over the past 3 years, Keros Therapeutics' median Accounts Payables value was $5.0 million (recorded in 2024), while the average stood at $4.9 million.
  • In the last 5 years, Keros Therapeutics' Accounts Payables crashed by 71.72% in 2021 and then skyrocketed by 458.31% in 2022.
  • Keros Therapeutics' Accounts Payables (Quarterly) stood at $3.6 million in 2021, then decreased by 8.40% to $3.3 million in 2022, then skyrocketed by 63.22% to $5.5 million in 2023, then decreased by 15.56% to $4.6 million in 2024, then crashed by 53.86% to $2.3 million in 2025.
  • Its Accounts Payables stands at $2.3 million for Q3 2025, versus $5.3 million for Q2 2025 and $6.6 million for Q1 2025.